Cosentyx

Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
Clear skin within reach for psoriasis patientsNew data presented at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, this week shows that secukinumab (Cosentyx, Novartis) has long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis.
Novartis announces new Cosentyx data in psoriasis treatment, including long-term studyResearchers presented new data on the use of the fully human IL-17A inhibitor Cosentyx (secukinumab, Novartis) in moderate-to-severe psoriasis, at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, September 28 through October 2, 2016.
Cosentyx gets thumbs up for 2 new indicationsFDA has approved secukinumab (Cosentyx, Novartis) for the treatment of adult patients with active ankylosing spondylitis and active psoriatic arthritis.
New psoriasis therapies must demonstrate valuePsoriasis affects a small percentage of the population but price increases for drug treatments have outpaced the Consumer Price Index.
Secukinumab shows benefit in psoriatic arthritis patientsSecukinumab may be an important new therapeutic treatment option for patients with psoriatic arthritis (PsA), according to a study published online in The New England Journal of Medicine.
Cosentyx demonstrates benefit over 1 year in psoriatic arthritis patientsNovartis’ new injectable drug secukinumab (Cosentyx) showed significant improvements in treating psoriatic arthritis (PsA), according to a new study.
AAD 2015: Secukinumab improves skin clearance in plaque psoriasis patients over widely used therapyPlaque psoriasis patients treated with secukinumab (Cosentyx) over ustekinumab (Stelara)—a widely used biologic—can achieve clearer skin, according to a late-breaking research session at the 73rd Annual Meeting of the American Academy of Dermatology (AAD), in San Francisco.
FDA approves secukinumab for moderate-to-severe plaque psoriasisFDA has approved secukinumab (Cosentyx, Novartis) for the treatment of moderate-to-severe plaque psoriasis.
FDA drug approvals-January 2015FDA actions in brief, recommendations for approval, fast-track designations.